Discngine, a Paris, France-based software company specializing in applications for life sciences research, raised €1.1m ($1.3M) in Series A financing.
Extens Développement e-Santé provided the funds.
The company intends to use the funds to speed up the development and commercialization of its SaaS solution offering, to extend its international reach, as well as to hire ten new staff members by the end of 2018.
Established in 2004 by two of Pfizer’s research alumni, Discngine specializes in applications for the research departments of life sciences companies; specifically for work related to active molecule discovery. The company’s offering has historically been developed around custom software, followed by licenses for software components and most recently by licenses for business solutions. It will now focus on offering catalog products through SaaS and cloud-based subscription models. To this end, Discngine is already collaborating with Dassault Systèmes BIOVIA on the distribution of its first two SaaS solutions. It is also planning to launch new solutions dedicated to life sciences research in 2018.
Led by Eric Le Roux, founder and CEO, the company currently has 38 employees and clients include world leaders in the pharmaceutical, cosmetics and agrochemical industries.